Brokerages Set Vital Therapies, Inc. (VTL) Price Target at $8.00

Vital Therapies, Inc. (NASDAQ:VTL) has received an average recommendation of “Hold” from the six research firms that are currently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation, two have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $8.00.

A number of analysts recently issued reports on the company. Zacks Investment Research downgraded Vital Therapies from a “hold” rating to a “sell” rating in a research report on Thursday, October 5th. BidaskClub raised Vital Therapies from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 5th.

COPYRIGHT VIOLATION NOTICE: “Brokerages Set Vital Therapies, Inc. (VTL) Price Target at $8.00” was posted by Markets Daily and is the sole property of of Markets Daily. If you are accessing this report on another site, it was illegally stolen and reposted in violation of international trademark & copyright law. The legal version of this report can be read at https://www.themarketsdaily.com/2017/10/11/brokerages-set-vital-therapies-inc-vtl-price-target-at-8-00.html.

In other news, Director Jean Jacques Bienaime bought 10,000 shares of the company’s stock in a transaction on Wednesday, September 13th. The stock was bought at an average cost of $4.00 per share, with a total value of $40,000.00. Following the transaction, the director now directly owns 65,119 shares in the company, valued at approximately $260,476. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Muneer A. Satter bought 130,000 shares of the company’s stock in a transaction on Thursday, September 14th. The stock was purchased at an average cost of $4.01 per share, with a total value of $521,300.00. The disclosure for this purchase can be found here. Insiders have purchased a total of 190,000 shares of company stock valued at $737,800 over the last three months. Corporate insiders own 32.60% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. UBS Oconnor LLC acquired a new position in Vital Therapies in the 1st quarter valued at about $800,000. FMR LLC grew its position in Vital Therapies by 102.9% in the 1st quarter. FMR LLC now owns 2,957,878 shares of the company’s stock valued at $11,832,000 after acquiring an additional 1,500,000 shares in the last quarter. SG Americas Securities LLC acquired a new position in Vital Therapies in the 1st quarter valued at about $167,000. Blair William & Co. IL grew its position in Vital Therapies by 67.2% in the 2nd quarter. Blair William & Co. IL now owns 99,500 shares of the company’s stock valued at $289,000 after acquiring an additional 40,000 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its position in Vital Therapies by 11.5% in the 1st quarter. Bank of New York Mellon Corp now owns 88,104 shares of the company’s stock valued at $352,000 after acquiring an additional 9,120 shares in the last quarter. 25.58% of the stock is owned by institutional investors.

Vital Therapies (NASDAQ VTL) remained flat at $5.55 on Thursday. The stock had a trading volume of 74,509 shares. The stock has a 50-day moving average price of $4.23 and a 200 day moving average price of $3.45. The company’s market cap is $234.25 million. Vital Therapies has a 52 week low of $2.25 and a 52 week high of $6.50.

Vital Therapies (NASDAQ:VTL) last issued its quarterly earnings data on Thursday, August 3rd. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.01. During the same period last year, the company earned ($0.30) EPS. Equities research analysts forecast that Vital Therapies will post ($1.31) earnings per share for the current year.

About Vital Therapies

Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.

Receive News & Ratings for Vital Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply